P2Y12, a New Platelet ADP Receptor, Target of Clopidogrel
- 4 May 2001
- journal article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 283 (2), 379-383
- https://doi.org/10.1006/bbrc.2001.4816
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- ADP Is the Cognate Ligand for the Orphan G Protein-coupled Receptor SP1999Published by Elsevier BV ,2001
- Identification of the platelet ADP receptor targeted by antithrombotic drugsNature, 2001
- Identification and Biological Activity of the Active Metabolite of ClopidogrelThrombosis and Haemostasis, 2000
- Role of P2Y1 purinoceptor in ADP‐induced platelet activationFEBS Letters, 1998
- Characterization of P2x1 purinoreceptors on rat platelets: effect of clopidogrel.British Journal of Haematology, 1997
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996
- Rapid isolation of highly productive recombinant Chinese hamster ovary cell linesGene, 1994
- Clopidogrel, A Novel Antiplatelet and Antithrombotic AgentCardiovascular Drug Reviews, 1993
- Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1992
- Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity.Proceedings of the National Academy of Sciences of the United States of America, 1980